April 12 (Reuters) - Mauna Kea Technologies SAS MKEA.PA :
* ANNOUNCES THE FIRST FDA 510(K) CLEARANCE FROM THE FDA FOR
THE
USE OF CELLVIZIO IN A NEW CLASS OF ENDOSCOPIC, LAPAROSCOPIC AND
NEEDLE-BASED PROCEDURES GUIDED BY MOLECULAR IMAGING
* THIS U.S. FDA CLEARANCE IS FOR A NEW CLINICAL INDICATION
FOR THE
USE OF CELLVIZIO IN FLUORESCENCE IMAGING OF TISSUES TARGETED BY
A MOLECULAR MARKER, PAFOLACIANIN, MARKETED AS CYTALUX™ AND
MANUFACTURED BY ON TARGET LABORATORIES
Source text: [https://bit.ly/37Jw9IQ]
Further company coverage: MKEA.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))